Background: PROSELICA (NCT01308580) assessed the non-inferiority of cabazitaxel 20 mg/m 2 (C20) vs 25 mg/m 2 (C25) in patients (pts) with mCRPC post docetaxel, while FIRSTANA (NCT01308567) investigated whether C20 and C25 were superior to docetaxel 75 mg/m 2 (D75) in chemotherapy-naive mCRPC. This analysis evaluated the impact of cabazitaxel on HRQL in both trials. Methods: Alongside pain and analgesic score, HRQL was assessed using the Functional Assessment of Cancer Therapy Prostate (FACT-P) questionnaire. The analysis focused on FACT-P (clinically meaningful improvement or deterioration of total score [TS]) among responders. Results: Pt baseline characteristics are shown in the table. In PROSELICA, 57.2% and 59.4% of pts receiving C20 and C25 had FACT-P TS improvements; in FIRSTANA, 63.5%, 62.3% and 57.7% of pts receiving C20, C25 and D75 had FACT-P TS improvements. In FACT-P responders, FACT-P TS improvements occurred as early as Cycle (C) 1 (mean change from baseline: PROSELICA C20 10.4, n ¼ 264; C25 10.6, n ¼ 266; FIRSTANA C20 11.7, n ¼ 206; C25 11.7, n ¼ 202; D75 9.0, n ¼ 195); these were largely maintained. For pts with a pain response in PROSELICA, FACT-P TS improvements occurred as early as C1 (C20 6.8, n ¼ 71; C25 11.1, n ¼ 81) and were maintained until C8 (C20 10.6, n ¼ 43; C25 9.6, n ¼ 44). In FIRSTANA, FACT-P TS improvements in pts with a pain response were seen as early as C1 or C2 (C1: C20 15.5, n ¼ 41; C25 12.5, n ¼ 41; D75, 7.9, n ¼ 32) and maintained until C9 (C20 9.0, n ¼ 27; C25 10.5, n ¼ 26; D75 16.4, n ¼ 20). In pts with a tumor or PSA response, HRQL was maintained for all treatment arms in both studies. Additional results for clinical responder subgroups and FACT-P subscales will be presented.
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Conclusions:
More than half of the pts experienced HRQL improvements, which were maintained. Pts with a pain response experienced HRQL improvements. C20, cabazitaxel 20 mg/m 2 ; C25, cabazitaxel 25 mg/m 2 ; D75, docetaxel 75 mg/m 2 ; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FACT-P TS, Functional Assessment of Cancer Therapy Prostate Total Score; PSA, prostate-specific antigen; SD, standard deviation. and 2.13 [1.75 -2.59] in G3 compared to G1. In multivariate analysis, pain at randomization was the strongest predictor of poor OS: HR Background: Platinum compounds have been tested in a larger number of mostly small to medium sized clinical trials in molecularly unselected prostate cancer patients (pts). Advances in castration-resistant prostate cancer (CRPC) molecular profiling have shown that a significant proportion of pts harbor DNA repair defects, which may serve as predictive markers for sensitivity to platinum agents. Our aim was to evaluate the antitumour activity of platinum agents in a contemporaneous mCRPC cohort with or without DNA repair defects. Methods: International, multicenter retrospective database project in 14 centers worldwide. Pts with mCRPC treated with a platinum agent were included. Pts with primary pure small cell carcinoma and/or insufficient outcome data were excluded. For antitumour activity PSA levels at baseline, after 4-, 8-and 12-weeks of therapy (tx) were analyzed as well as soft tissue response and duration of platinum-based chemotherapy. Overall survival (OS) was analyzed by Kaplan Meier method. Results: A total of 167 pts have been included in this analysis, 33 (20%) received platinum monotherapy, 134 (80%) a platinum combination therapy. Carboplatin was used in 140 (84%), cisplatin in 26 (16%) of pts. Combination tx with etoposise was used in 45 (27%), paclitaxel in 35 (21%) and docetaxel in 28 (17%) of pts. At start of platinum tx median age was 68 years, median PSA 78 ug/l, median ALP 185 U/l, median hemoglobin 103 g/l. The metastatic sites at start of platinum therapy were: bone 84%, lymph node 59% and visceral 60%. Outcome data by DNA repair defect status are summarized in the table. 
